KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update KalVista Pharmaceuticals (Nasdaq: KALV) reported results for the eight months ended December 31, 2025, following a fiscal-year change. EKTERLY generated $49.1 million global net product revenue since launch and recorded 1,702 US patient start forms through February 28, 2026 (about 20% of the US patient population).Key clinical progress includes completed pediatric Phase 3 enrollment and planned US NDA filing in Q3 2026; cash and marketable securities were approximately $300.2 million at year-end.

#KALV KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/KALV/kal-vista-phar...

KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat) KalVista (Nasdaq: KALV) reported new clinical data showing high patient satisfaction and shifting treatment behavior with oral EKTERLY (sebetralstat). In KONFIDENT-S, patients treated 2,464 attacks with sebetralstat; 83.1% of treated attacks rated satisfied or better and use of injectables fell with repeated use.Analyses showed treating within 30 minutes predicted faster symptom relief, with simulations suggesting nearly 90% might experience relief within 12 hours.

#KALV KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)

www.stocktitan.net/news/KALV/kal-vista-phar...

KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema KalVista Pharmaceuticals (Nasdaq: KALV) announced that Japan's Ministry of Health, Labor and Welfare granted marketing and manufacturing approval for EKTERLY (sebetralstat) as an oral on-demand treatment for acute hereditary angioedema (HAE) attacks in adults and adolescents aged 12 and older.EKTERLY is the first and only oral on-demand HAE treatment approved in Japan and will be commercialized in Japan by partner Kaken Pharmaceutical, which plans to launch after EKTERLY is listed on the Japanese National Health Insurance system. Approval relied on the phase 3 KONFIDENT trial—the largest HAE study (136 patients, 66 sites, 20 countries)—with results published in the New England Journal of Medicine showing faster symptom relief, reduced attack severity, and attack resolution versus placebo. Since July 3, 2025, EKTERLY has received seven regulatory approvals across major markets.

#KALV KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema

www.stocktitan.net/news/KALV/kal-vista-phar...

Leading Indicators, Wednesday December 3, 2025 – Crystal Equity Research

Small-cap stocks with strong volume gains, Wed Dec 3rd - #TROO #RR #QCLS #PHVS #MNTS #KITT #KALV #IRBT #HTOO #FRST #DBVT #CAPR #BCTX #ABTC #WDH #NLOP #DSX #CXM - More: crystalequityresearch.com/leading-indi... - #smallcap

KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results KalVista Pharmaceuticals (Nasdaq: KALV) reported third-quarter 2025 results and an operational update focused on the commercial launch of EKTERLY. The company recognized $13.7M in net product revenue for Q3 and received 937 patient start forms through October with 423 unique prescribers activated. EKTERLY launched in Germany and received approvals in the EU, Switzerland and Australia. KalVista closed a $144M convertible note and held $309.2M in cash and marketable securities as of September 30, 2025.R&D declined to $12.0M and SG&A rose to $46.5M in Q3 2025, reflecting commercialization activity.

#KALV KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results

www.stocktitan.net/news/KALV/kal-vista-phar...

KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe KalVista Pharmaceuticals (Nasdaq: KALV) presented new European data showing oral EKTERLY (sebetralstat) rapidly halts hereditary angioedema (HAE) attacks and addresses barriers tied to injectable on-demand therapies. Key clinical findings: a median 20 minutes to end of attack progression across KONFIDENT and KONFIDENT-S, and KONFIDENT-S interim data (69 participants, 999 treated attacks) reporting a median time to treatment of 16 minutes (10 minutes in adolescents) and median 1.6 hours to symptom relief. A German patient survey (49 respondents) found a mean time to treatment of 3.9 hours, only 18% treated within 1 hour, and 53% experienced injection-site reactions, highlighting uptake barriers for injectables. EKTERLY is approved in the European Union with a planned Germany launch this quarter and additional European launches in 2026.

#KALV KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe

www.stocktitan.net/news/KALV/kal-vista-phar...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#PAAS, #KALV, #LAES, #ESI, #MS

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #PEPG 6.3x
2. #AMPY 4.5x
3. #ESI 4.0x
4. #XPEV 3.3x
5. #KALV 3.1x

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#ESI, #KALV, #TJX, #RXRX, #NVS

#OptionFlow #OptionsTrading #Trading

$125M Biotech Funding: KalVista Secures Convertible Notes at 3.25% for EKTERLY Commercialization Push Biotech firm KalVista prices $125M convertible senior notes at 3.25%, due 2031, with $16.81 conversion price. Proceeds to fund EKTERLY commercialization and general corporate purposes.

#KALV KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031

www.stocktitan.net/news/KALV/kal-vista-pric...

KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes KalVista Pharmaceuticals (NASDAQ: KALV) has announced plans to offer $110.0 million in Convertible Senior Notes due 2031 through a private placement to qualified institutional buyers. The company will grant initial purchasers an option for an additional $15.0 million in notes. The notes will be senior, unsecured obligations with semi-annual interest payments.The notes will mature on October 1, 2031, with conversion options available under specific conditions. KalVista can settle conversions in common stock, cash, or a combination thereof. The company plans to use the proceeds for working capital, general corporate purposes, and the commercialization of EKTERLY, with potential allocation for future investments and acquisitions.

#KALV KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes

www.stocktitan.net/news/KALV/kal-vista-phar...

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#KIDZ, #KALV, #ADBE, #NEXT, #VRT

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #SOC 65% OTM
2. #BE 57% OTM
3. #KALV 31% OTM
4. #KIDZ 31% OTM
5. #ADBE 26% OTM

#OptionFlow #OptionsTrading #Trading

Biotech Update: KalVista Pharmaceuticals (KALV) Announces Q2 2025 Financial Results Date and Operations Review KalVista Pharmaceuticals will host webcast on September 11, 2025 at 8:30 AM ET to discuss Q2 fiscal 2025 financial results and provide operational updates. Replay available for 30 days.

#KALV KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025

www.stocktitan.net/news/KALV/kal-vista-phar...

Breakthrough Oral HAE Drug Secures Rare EU Orphan Status: 10-Year Market Protection Ahead Novel oral treatment sebetralstat maintains coveted EU orphan drug status for hereditary angioedema. Learn how this positions KalVista for market dominance. See details.

#KALV KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union

www.stocktitan.net/news/KALV/kal-vista-phar...

Revolutionary First-Ever Oral HAE Treatment Gets Key EU Support, October Decision Looms KalVista's sebetralstat set to transform HAE attack treatment from injections to pills in EU. Final approval expected October 2025. See clinical trial results.

#KALV KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks

www.stocktitan.net/news/KALV/kal-vista-phar...

Breakthrough: First-Ever Oral HAE Treatment EKTERLY Secures UK Approval and Decade-Long Market Protection KalVista's EKTERLY makes history as first oral treatment for hereditary angioedema attacks, securing UK approval and 10-year market exclusivity. See clinical data.

#KALV KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

www.stocktitan.net/news/KALV/kal-vista-phar...

KalVista's Breakthrough: First-Ever Oral Drug for HAE Attacks Gets FDA Green Light KalVista's EKTERLY revolutionizes HAE treatment as first oral therapy. Global expansion underway with Japan, Canada deals. See clinical efficacy data.

#KALV KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results

www.stocktitan.net/news/KALV/kal-vista-phar...

KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema KalVista Pharmaceuticals (NASDAQ:KALV) has received FDA approval for EKTERLY® (sebetralstat), marking a significant breakthrough as the first and only oral on-demand treatment for hereditary angioedema (HAE) attacks in patients aged 12 and older.The approval is based on the KONFIDENT phase 3 trial, the largest HAE clinical trial to date, which demonstrated significantly faster symptom relief and attack resolution compared to placebo. The KONFIDENT-S extension trial showed median symptom relief beginning at 1.3 hours for various attack types, with patients able to initiate treatment within 10 minutes of attack onset.EKTERLY is immediately available in the U.S., supported by KalVista Cares™, a comprehensive patient support program. This approval represents the first new on-demand HAE treatment in over a decade, offering an alternative to existing injectable treatments.

#KALV KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

www.stocktitan.net/news/KALV/kal-vista-phar...

KalVista's Breakthrough Oral HAE Drug Sebetralstat Secures Canadian Partnership: First-Ever Pill Treatment KalVista partners with Pendopharm to bring first-ever oral treatment for hereditary angioedema to Canadian market. Discover expansion strategy details.

#KALV KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada

www.stocktitan.net/news/KALV/kal-vista-phar...

Just In: ( NASDAQ: #KALV ) KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis

KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints KalVista Pharmaceuticals announced that the FDA will not meet the June 17, 2025 PDUFA goal date for reviewing the New Drug Application (NDA) of sebetralstat, their oral on-demand treatment for hereditary angioedema (HAE). The delay is attributed to FDA's heavy workload and limited resources, with an expected decision within approximately four weeks. Importantly, the FDA has not requested additional data or studies and has not raised concerns about safety, efficacy, or approvability. KalVista has addressed all prior information requests, with only label finalization remaining under review. CEO Ben Palleiko expressed disappointment but maintained confidence in near-term approval.

#KALV KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints

www.stocktitan.net/news/KALV/kal-vista-phar...

New Clinical Data: Revolutionary Oral HAE Treatment Stops Attacks in Under 20 Minutes, Transforms Patient Care Latest trial results reveal sebetralstat's rapid attack control and effectiveness in severe HAE cases. See breakthrough data on mucosal attack treatment times.

#KALV KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management

www.stocktitan.net/news/KALV/kal-vista-phar...

Major Breakthrough: KalVista's Oral HAE Drug Secures $22M Japanese Partnership First potential oral HAE treatment in Japan: KalVista partners with Kaken Pharma, securing $11M upfront plus milestone payments. See deal implications and market potential.

#KALV KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan

www.stocktitan.net/news/KALV/kal-vista-phar...

Breakthrough Pediatric HAE Drug Trial Hits Major Milestone: Patient Demand Surges 50% Novel oral treatment for children with HAE sees unprecedented trial demand, completing enrollment one year early. Could revolutionize treatment for ages 2-11. Full analysis inside.

#KALV KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial

www.stocktitan.net/news/KALV/kal-vista-phar...

💊 KalVista (KALV) is advancing its HAE treatment pipeline, securing key regulatory progress. 🚀 Could this biotech breakthrough drive long-term investor growth? Full analysis here: buff.ly/vsHQU9L #KalVista #KALV #BiotechStocks #HAETreatment #Investing

KalVista's Oral HAE Treatment Delivers 76-Minute Relief as FDA Review Nears Sebetralstat demonstrates rapid symptom relief in HAE patients as KalVista strengthens position with $253M cash reserve and expanded regulatory submissions for 2025 approval.

#KALV KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

www.stocktitan.net/news/KALV/kal-vista-phar...

Revolutionary Oral HAE Treatment From KalVista Achieves 96% Effectiveness in Minutes New data shows sebetralstat provides rapid symptom relief for hereditary angioedema attacks, including in adolescents and laryngeal cases, with single-dose effectiveness.

#KALV KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

www.stocktitan.net/news/KALV/kal-vista-phar...

Critical HAE Treatment Breakthrough: KALV's Sebetralstat Delivers Relief in 78 Minutes While Current Therapies Fall Short New clinical data shows KalVista's sebetralstat achieves rapid symptom relief for HAE attacks in 1.3 hours, effective across all prophylaxis types with early treatment option.

#KALV KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting

www.stocktitan.net/news/KALV/kal-vista-phar...